Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2010

View Archived Issues

Truvada well tolerated in HIV-1-infected pregnant women and neonates

QNL-111 shown to inhibit HIV-1 DNA integration

Vicriviroc does not meet primary endpoint in two phase III trials in HIV

C5A inhibits HIV-1 and HSV in preclinical studies

Pfizer describes novel kappa opioid receptor antagonists

Novel serotonin 5-HT6 receptor antagonists patented by Janssen

Bristol-Myers Squibb discloses new transcription factor AP-1 inhibitors

Merck KGaA identifies novel PDK1 inhibitors

Ambit Biosciences claims novel Janus kinase inhibitors

Novel dual PI3K alpha and mTOR inhibitors described by S*BIO

Resverlogix activates first site in phase II ASSURE 1 trial of RVX-208 in ACS

Fourth quarter highlights at Merck & Co.

Adeona completes 50% of enrollment in Trimesta trial in multiple sclerosis

GlycoVaxyn begins clinical trial of bioconjugate GVXN-SD-133 Shigella vaccine

Akebia initiates phase Ib trial of AKB-6548 for anemia

Fluticasone nasal spray ineffective in irritant rhinitis in pilot trial

TMTI awards SIGA contract for development broad-spectrum antiviral ST-669

Global Health Ventures to begin European trials of X-Excite for erectile dysfunction

Corcept Therapeutics begins phase I CORT-108297 trial

Rockwell Medical reports phase IIb data on soluble ferric pyrophosphate

Johnson & Johnson reviews fourth quarter of 2009

Actelion reports on BUILD-3 trial of bosentan in idiopathic pulmonary fibrosis

FDA issues refuse to file letter to Adventrx on vinorelbine NDA

Virginia G. Piper Cancer Center and TGen begin phase I trial of Pharmacyclics' PCI-32765 in cancer

FDA grants marketing approval for Shire's VPRIV for type 1 GD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...